Table 1: Study characteristics following pretherapeutic allocation.
Variable |
RPVE Mean, (SD), resp.% |
EBRT Mean, (SD), resp.% |
P |
Study participants |
493 |
249 |
|
Age |
66.70 (6.52) |
72.55 (6.56) |
< 0.0001 |
Proportion positive biopsies |
0.40 (0.27) |
0.36 (0.14) |
0.4612 |
Gleason-score |
5.79 (1.61) |
6,68 (1.14) |
< 0.0001 |
D’Amico-score |
2.88 (1.44) |
2.52 (1.43) |
0.0004 |
Charlson Comorbidity -Index |
0.68 (0.90) |
1.14 (1.09) |
< 0.0001 |
Prostate volume |
42.95 (20.22) |
30.07 (17.57) |
< 0.0001 |
PSA |
11.14 (12.64) |
12.62 (15.20) |
0.4339 |
Stage cT1a-cT1c cT2a-cT2b |
60.8% 67.7% |
39.2% 32.3% |
< 0.0001 < 0.0001 |
cT2c |
78.1% |
21.9% |
< 0.0001 |
cT3a-cT3b |
35.7% |
64.3% |
< 0.0001 |